EUVIMEDEUVIMED entdecken
Open Access

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy

Sabina Kaczanowska, Tara Murty, Ahmad Alimadadi, Cristina F Contreras, Caroline Duault, Priyanka B Subrahmanyam, Warren Reynolds, Norma A Gutierrez, Reema Baskar, Catherine J Wu, Franziska Michor, Jennifer Altreuter und 32 weitere

Cancer Cell · 2024

DOI: 10.1016/j.ccell.2023.11.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024. Verfasst von Sabina Kaczanowska und 43 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neuroblastoma. Die Arbeit wurde bisher 124-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T cells (CAR-Ts) have remarkable efficacy in liquid tumors, but limited responses in solid tumors. We conducted a Phase I trial (NCT02107963) of GD2 CAR-Ts (GD2-CAR.OX40.28.z.iC9), demonstrating feasibility and safety of administration in children and young adults with osteosarcoma and neuroblastoma. Since CAR-T efficacy requires adequate CAR-T expansion, patients were grouped into good or poor expanders across dose levels. Patient samples were evaluated by multi-dimensional proteomic, transcriptomic, and epigenetic analyses. T cell assessments identified naive T cells in pre-treatment apheresis associated with good expansion, and exhausted T cells in CAR-T products with poor expansion. Myeloid cell assessment identified CXCR3+ monocytes in pre-treatment apheresis associated with good expansion. Longitudinal analysis of post-treatment samples identified increased CXCR3- classical monocytes in all groups as CAR-T numbers waned. Together, our data uncover mediators of CAR-T biology and correlates of expansion that could be utilized to advance immunotherapies for solid tumor patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeuroblastomaChildYoung AdultHumansReceptors, Antigen, T-CellProteomicsImmunotherapy, AdoptiveT-LymphocytesCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

CAR-T cellscancerchimeric antigen receptorcorrelative studiesimmune suppressionimmunotherapymonocytesmyeloid cellsosteosarcomapediatric oncologysolid tumor

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • La Jolla Institute for Immunology, La Jolla, CA, USA; Immunology Center of Georgia, Augusta University, Augusta, GA, USA; Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA, USA.
  • Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Department of Oncology, University of Oxford, Oxford, UK.
  • Stanford Human Immune Monitoring Center, Stanford University School of Medicine, Stanford, CA, USA.
  • La Jolla Institute for Immunology, La Jolla, CA, USA.

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • Intramural NIH HHS
  • AbbVie
  • Dana-Farber Cancer Institute
  • National Institutes of Health
  • Foundation for the National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Kaczanowska, S., Murty, T., Alimadadi, A., Contreras, C. F., Duault, C., Subrahmanyam, P. B., Reynolds, W., Gutierrez, N. A., Baskar, R., Wu, C. J., Michor, F., Altreuter, J., Liu, Y., Jhaveri, A., Duong, V., Anbunathan, H., Ong, C., Zhang, H., Moravec, R., …, & Kaplan, R. N. (2024). Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell. https://doi.org/10.1016/j.ccell.2023.11.011

Vancouver

Kaczanowska S, Murty T, Alimadadi A, Contreras CF, Duault C, Subrahmanyam PB, et al. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell. 2024. doi:10.1016/j.ccell.2023.11.011

BibTeX
@article{Kaczanowska2024,
  author = {Kaczanowska, Sabina and Murty, Tara and Alimadadi, Ahmad and Contreras, Cristina F and Duault, Caroline and Subrahmanyam, Priyanka B and Reynolds, Warren and Gutierrez, Norma A and Baskar, Reema and Wu, Catherine J and Michor, Franziska and Altreuter, Jennifer and Liu, Yang and Jhaveri, Aashna and Duong, Vandon and Anbunathan, Hima and Ong, Claire and Zhang, Hua and Moravec, Radim and Yu, Joyce and Biswas, Roshni and Van Nostrand, Stephen and Lindsay, James and Pichavant, Mina and Sotillo, Elena and Bernstein, Donna and Carbonell, Amanda and Derdak, Joanne and Klicka-Skeels, Jacquelyn and Segal, Julia E and Dombi, Eva and Harmon, Stephanie A and Turkbey, Baris and Sahaf, Bita and Bendall, Sean and Maecker, Holden and Highfill, Steven L and Stroncek, David and Glod, John and Merchant, Melinda and Hedrick, Catherine C and Mackall, Crystal L and Ramakrishna, Sneha and Kaplan, Rosandra N},
  title = {Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy},
  journal = {Cancer Cell},
  year = {2024},
  doi = {10.1016/j.ccell.2023.11.011}
}
Kostenlos starten →